Regeneron Pharmaceuticals, Inc. (REGN)

NMS – Real Time Price. Currency in USD

723.41

+10.64 (1.49%)

At close: May 12, 2026, 4:00 PM EDT

722.50

-0.91 (-0.13%)

After-hours: May 12, 2026, 7:50 PM EDT

12.05.2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

08.05.2026

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company's recent announcement that it will provide its new gene therapy for a form of genetic hearing loss for free in the United States, reinforcing its commitment to patient access New science-led 2030 responsibility goals reflect Regeneron's commitment to corporate responsibility, from how it innovates to how it operates, for the good of its business and humanity TARRYTOWN, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced it has been named to the Dow Jones Best-in-Class World Index, one of the world's most recognized benchmarks for corporate sustainability performance.

05.05.2026

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients with EoE at week 24 compared to placebo, in results presented at DDW

30.04.2026

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) on Wednesday reported better-than-expected first-quarter financial results and announced a $3 billion share buyback.

30.04.2026

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

29.04.2026

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript

29.04.2026

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) on Wednesday reported first-quarter adjusted earnings of $9.47 per share, up 15% year-over-year, beating the consensus of $8.89.

Videos

24.04.2026

Negative

Regeneron CEO on deal with Trump admin to lower drug prices

12.01.2026

Neutral

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

10.12.2025

Neutral

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

12.11.2025

Neutral

Final Trade: LMAT, REGN, BA, TJX

Press releases

08.05.2026

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

05.05.2026

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

29.04.2026

Regeneron Reports First Quarter 2026 Financial and Operating Results

TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update.

23.04.2026

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.

Regeneron Pharmaceuticals, Inc. (REGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Videos

Press releases

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Reports First Quarter 2026 Financial and Operating Results

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Videos

Press releases

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Reports First Quarter 2026 Financial and Operating Results

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Search stocks

Regeneron Pharmaceuticals, Inc. (REGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Videos

Press releases

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Reports First Quarter 2026 Financial and Operating Results

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings

Why Regeneron (REGN) is a Top Value Stock for the Long-Term

Regeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call Transcript

Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe

Videos

Press releases

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Reports First Quarter 2026 Financial and Operating Results

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.